ECHDC1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa cell line, designed to disrupt the ethylmalonyl-CoA decarboxylase 1 (ECHDC1) gene. This polyclonal knockout product provides a heterogeneous loss-of-function model for studying the roles of ECHDC1 in mitochondrial fatty acid metabolism and protein acetylation, without introducing a specific clone-derived selection bias. The CRISPR/Cas9-mediated gene disruption targets the ECHDC1 locus, enabling researchers to investigate the downstream metabolic and signaling consequences of ECHDC1 ablation in a well-characterized human cell background.
The host HeLa cell line is an immortalized human epithelial cell line derived from a cervical adenocarcinoma, first established in 1951 from the biopsy of Henrietta Lacks. HeLa cells are widely utilized in biomedical research due to their robust growth, genetic stability, and extensive characterization in cancer biology, signal transduction, and metabolic studies. Their cervical cancer origin and high proliferative capacity make them a relevant model for exploring the intersection of oncogenic signaling and cellular metabolism, particularly in the context of lipid and acetyl-CoA homeostasis.
ECHDC1 encodes a mitochondrial enzyme that catalyzes the decarboxylation of ethylmalonyl-CoA to butyryl-CoA, a reaction integral to mitochondrial fatty acid synthesis and the regulation of protein acetylation. This enzyme operates within a network of fatty acid ??-oxidation and branched-chain amino acid catabolism, interacting with key mitochondrial proteins such as ACADVL, HADHA, and ECHS1. ECHDC1 activity is influenced by upstream regulators including PPAR??, AMPK, and the deacetylase SIRT1, and it contributes to downstream processes like histone acetylation and metabolic flux into the tricarboxylic acid (TCA) cycle. The interplay among these factors positions ECHDC1 at a node connecting nutrient sensing, redox balance, and epigenetic regulation.
In HeLa cells, disruption of ECHDC1 is expected to cause accumulation of ethylmalonyl-CoA and a concomitant reduction in butyryl-CoA and acetyl-CoA pools. Such metabolic alterations can impair mitochondrial fatty acid metabolism, alter global protein acetylation profiles, and disrupt cellular energy homeostasis. Given the reliance of cancer cells on metabolic reprogramming for proliferation and survival, this knockout model offers a platform to dissect how ECHDC1-dependent metabolic fluxes impact oncogenic phenotypes, including changes in growth factor signaling, cell cycle progression, and apoptotic sensitivity.
This polyclonal knockout cell population is well-suited for quantitative metabolomic studies using liquid chromatography-mass spectrometry (LC-MS) to measure ethylmalonyl-CoA and acetyl-CoA levels, Seahorse-based metabolic flux assays to assess mitochondrial respiration and glycolysis, and western blotting to evaluate global protein acetylation changes. Additional applications include RT-qPCR profiling of metabolic gene expression, proliferation and colony formation assays under varied nutrient conditions, and high-throughput screening of small-molecule modulators targeting metabolic pathways in cancer. For technical inquiries or access to customized gene-edited cell models, please contact Ascent Research.
